Skip to main content

Advertisement

Log in

Effects of daily tadalafil on lower urinary tract symptoms in young men with multiple sclerosis and erectile dysfunction: a pilot study

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Purpose

Men affected by multiple sclerosis often experience neurogenic overactive bladder (OAB), lower urinary tract symptoms and erectile dysfunction (ED). The aim of the study was to investigate modifications of urinary and sexual functions after administration of daily tadalafil (TAD) 5 mg.

Methods

Twenty men were enrolled in a single-blind, 4-week prospective study while 10 men without treatment served as controls. Primary outcomes were changes from baseline of International Prostate Symptom (IPSS), OAB questionnaire (OAB-q-short form) and International Index of Erectile Function (IIEF-5) scores. To evaluate the influence of bladder filling on somatic reflexes, we studied variations of the H-reflex evoked by electrical stimuli applied to the tibial nerve at the popliteal fossa and recorded from the soleus muscle. Also testosterone/estradiol (T/E) ratio was measured before and after treatment.

Results

In TAD group, an improvement in IPSS (p < 0.001), OAB-q (p < 0.001) and IIEF-5 (p < 0.001) scores was found. Also, an increase in Q max (p < 0.01) and T/E ratio (p < 0.01) was found with a concomitant reduction in post-void residual volume (p < 0.001) without any changes in the H-reflex.

Conclusions

The study demonstrates for the first time that daily TAD in patients with multiple sclerosis improves storage symptoms, post-void residual volume, steroid hormone pattern and ED without urodynamic changes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Leboeuf L, Cohen B, Gousse AE (2008) Multiple sclerosis. In: Corcos J, Schick E (eds) Textbook of the neurogenic bladder. CRC Press, Boca Raton, pp 294–311

    Chapter  Google Scholar 

  2. Oppenheimer DR (1978) The cervical cord in multiple sclerosis. Neuropathol Appl Neurobiol 4:151–162

    Article  CAS  PubMed  Google Scholar 

  3. Fernandez O (2002) Mechanisms and current treatments of urogenital dysfunction in multiple sclerosis. J Neurol 249:1–8

    Article  PubMed  Google Scholar 

  4. Quarto G, Autorino R, Gallo A et al (2007) Quality of life in women with multiple sclerosis and overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 18:189–194

    Article  PubMed  Google Scholar 

  5. Ebers GC, Sadovnick AD, Risch NJ (1995) A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 377:150–151

    Article  CAS  PubMed  Google Scholar 

  6. Poser CM (1994) The epidemiology of multiple sclerosis: a general overview. Ann Neurol 36:S180–S193

    Article  PubMed  Google Scholar 

  7. Kanai A, Andersson KE (2010) Bladder afferent signaling: recent findings. J Urol 183:1288–1295

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Andersson KE (2011) Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol 59:377–386

    Article  CAS  PubMed  Google Scholar 

  9. Chapple CR, Roehrborn CG, McVary K et al (2015) Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trials. Eur Urol 67:114–122

    Article  CAS  PubMed  Google Scholar 

  10. Pofi R, Gianfrilli D, Badagliacca R et al (2016) Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work? J Endocrinol Invest 39:131–142

    Article  CAS  PubMed  Google Scholar 

  11. Burks J, Chancellor M, Bates D et al (2013) Development and validation of the actionable bladder symptom screening tool for multiple sclerosis patients. Int J MS Care Winter 15:182–192

    Article  Google Scholar 

  12. Radicioni A, Lenzi A, Spaziani M et al (2013) A multicenter evaluation of immunoassays for follicle-stimulating hormone, luteinizing hormone and testosterone: concordance, imprecision and reference values. J Endocrinol Invest 36:739–744

    Article  CAS  PubMed  Google Scholar 

  13. Conte A, Bettolo CM, Onesti E et al (2009) Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis. Eur J Pain 13:472–477

    Article  CAS  PubMed  Google Scholar 

  14. Lombardi G, Macchiarella A, Del Popolo G (2010) Efficacy and safety of tadalafil for erectile dysfunction in patients with multiple sclerosis. J Sex Med 7:2192–2200

    Article  PubMed  Google Scholar 

  15. Bruzziches R, Francomano D, Gareri P et al (2013) An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother 14:1333–1344

    Article  CAS  PubMed  Google Scholar 

  16. Uckert S, Stief CG (2011) Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors. Handb Exp Pharmacol 204:307–322

    Article  Google Scholar 

  17. Andersson KE, Uckert S, Stief C et al (2007) Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn 26:928–933

    Article  CAS  PubMed  Google Scholar 

  18. Yoshimura N, Skei S, de Groat WC (2001) Nitric oxide modulates Ca(2+) channels in dorsal root ganglion neurons innervating rat urinary bladder. J Neurophysiol 86:304–311

    CAS  PubMed  Google Scholar 

  19. Caremel R, Oger-Roussel S, Behr-Roussel D et al (2010) Nitric oxide/cyclic guanosine monophosphate signaling mediates an inhibitory action on sensory pathways of the micturition reflex in the rat. Eur Urol 58:616–625

    Article  CAS  PubMed  Google Scholar 

  20. Persson K, Igawa Y, Mattiasson A et al (1992) Effects of inhibition of the l-arginine/nitric oxide pathway in the rat lower urinary tract in vivo and in vitro. Br J Pharmacol 107:178–184

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Sesatomi K, Hiragata S, Miyazato M et al (2008) Nitric oxide-mediated suppression of detrusor overactivity by arginase inhibitor in rats with chronic spinal cord injury. Urology 72:696–700

    Article  Google Scholar 

  22. Artim DE, Kullman FA, Daughtery SL et al (2009) Activation of the nitric oxide-cGMP pathway reduces phasic contractions in neonatal rat bladder strips via protein kinase G. Am J Physiol Renal Physiol 297:F333–F340

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kanai A, Zabbarova I, Oefelein M et al (2012) Mechanisms of action of botulinum neurotoxins, b3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011. Neurourol Urodyn 31:300–308

    Article  CAS  PubMed  Google Scholar 

  24. Sculptoreanu A, Artim DE, de Groat WC (2009) Neurokinins inhibit low threshold inactivating K+ currents in capsaicin responsive DRG neurons. Exp Neurol 219:562–573

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Minegawa T, Aizawa N, Igawa Y et al (2012) Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat and on acrolien-induced hyperactivity of these nerves. BJU Int 110:E259–E266

    Article  Google Scholar 

  26. Aizawa N, Igawa Y, Nishizawa O et al (2011) Effects of nitric oxide on the primary bladder afferent activities of the rat with and without intravesical acrolein treatment. Eur Urol 59:264–271

    Article  CAS  PubMed  Google Scholar 

  27. Vignozzi L, Filippi S, Morelli A et al (2012) Testosterone/estradiol ratio regulates NO-induced bladder relaxation and responsiveness to PDE5 inhibitors. J Sex Med 9:3028–3040

    Article  CAS  PubMed  Google Scholar 

  28. Greco EA, Pili M, Bruzziches R et al (2006) Testosterone:estradiol ratio changes associated with long-term tadalafil administration: a pilot study. J Sex Med 3:716–722

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A. Aversa.

Ethics declarations

Conflict of interest

All the authors have no conflict of interest.

Ethical approval

The research involves human participants.

Informed consent

Each subject signed a detailed informed consent before entering the study.

Additional information

D. Francomano and A. Ilacqua have contributed equally to this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Francomano, D., Ilacqua, A., Cortese, A. et al. Effects of daily tadalafil on lower urinary tract symptoms in young men with multiple sclerosis and erectile dysfunction: a pilot study. J Endocrinol Invest 40, 275–279 (2017). https://doi.org/10.1007/s40618-016-0557-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-016-0557-y

Keywords

Navigation